This settlement demonstrates our commitment to enforcing patent rights, and our willingness to protect the competitive interests of our licensees. The funds received will be earmarked for clinical and product development programs, brand building for Chromax chromium picolinate, and the vigorous pursuit of our continuing patent enforcement efforts. Diane Cameron, President of Chemins, added, Chromax chromium picolinate is an important ingredient for Chemins and our customers. We now look forward to a productive future relationship between the two companies. Forward-looking statements are based on the company's current expectations and are subject to market, competitive and regulatory factors and the other risks and uncertainties indicated from time to time in the company's filings with the Securities and Exchange Commission.
Actual results can differ materially.
The company makes no commitment to disclose any revisions to forward-looking statements.